heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar) into the routine infant immunization schedule in the United States in 2000 has already reduced invasive pneumococcal disease overall, as well as invasive disease caused by penicillin-nonsusceptible (PCN-NS) pneumococci [2, 3] . In one controlled trial of a pneumococcal conjugate vaccine [4] , carriage of antimicrobial-resistant pneumococci decreased in vaccinated subjects. What is less clear is whether such decreases will be observed during introduction of the vaccine into the routine infant immunization schedule.
During the past decade, antimicrobial resistance among pneumococci has increased substantially [5] [6] [7] [8] . However, vaccination of infants with PCV7 may slow the increase in antimicrobial resistance among S. pneumoniae [9, 10] . Vaccination may reduce the prevalence of antimicrobial-resistant pneumococci among vacci-nees and their contacts, since the serotypes covered in the vaccine represent the majority of multidrug-resistant pneumococci [5] . Prelicensure studies have suggested that conjugate vaccines decrease acquisition of nasopharyngeal carriage of vaccine serotypes [11] [12] [13] [14] . Reductions in colonization with antimicrobial-resistant strains should result in both direct prevention of resistant pneumococcal disease among vaccinated individuals and reduced transmission of resistant strains to others.
In Alaska Native children, rates of invasive pneumococcal disease are among the highest documented in the world [15, 16] . Since 1990, the rates of antimicrobial resistance among S. pneumoniae throughout Alaska have increased substantially [17] . To understand the impact of the introduction of PCV7 into the routine infant immunization schedule in Alaska on pediatric colonization with antimicrobial-resistant S. pneumoniae, we conducted point-prevalence studies of nasopharyngeal carriage of pneumococci in urban Anchorage, Alaska, over the course of 3 years during which use of PCV7 vaccine was increasing.
PATIENTS, MATERIALS, AND METHODS

Patients.
In this observational, cross-sectional survey, patients were recruited consecutively from among children aged 3-59 months presenting to 3 clinics in Anchorage (a private clinic, a community clinic, and a clinic serving primarily children of Alaska Native descent) for either well-child or acute (nonemergency) care. One hundred fifty children were enrolled at each clinic during February and March of 2000-2002; children could be enrolled only once per year. No more than one child per household was recruited in any year.
After informed consent was obtained, we queried the parent or guardian regarding the subject's demographic information, risk factors for carriage of resistant bacteria, vaccine history, and use of antibiotics. The child's medical record was reviewed to document pneumococcal vaccinations (PCV7 or polysaccharide) and use of antibiotics and hospitalization during the 90 days before enrollment. The human-experimentation guidelines of the US Department of Health and Human Services and/or those of the authors' institutions were followed in the conduct of this research.
Procedures. A nasopharyngeal swab was collected from each study participant as described elsewhere [18] . Swabs were inoculated immediately onto sheep blood agar plates supplemented with 10 mg/mL gentamicin and were incubated in 5% CO 2 at 35ЊC-37ЊC within 30 min of collection.
Confirmed pneumococcal isolates were tested for susceptibility to penicillin by gradient strip diffusion (E-test; AB Biodisk) and to cotrimoxazole by agar dilution. Isolates with MICs to penicillin 10.064 mg/mL were defined as PCN-NS. Isolates with MICs у1/19 mg/mL were defined as cotrimoxazole nonsusceptible (COT-NS) [19] . Pulsed-field gel electrophoresis (PFGE) was performed as described elsewhere [20] .
Statistical analyses. Data were double entered into Paradox (version 9.0; Corel), and analyses were performed using SAS (version 9.0; SAS Institute). The Cochran-Mantel-Haenszel test and logistic regression were used in univariate analysis to identify factors potentially related ( ) to overall carriage and car-P ! .25 riage of PCV7-type, COT-NS, and PCN-NS pneumococci.
To estimate the effect of exposure to vaccine, we defined children as being up-to-date for age if they had received the recommended number of PCV7 doses [1] at the time of enrollment (algorithm available from the authors). We also estimated the impact of partial vaccination by comparing children who had received some PCV7 but were not up-to-date for age with children who had received no vaccine.
Variables identified in the univariate analysis were introduced into multivariate logistic regression models, to evaluate their independent contributions (expressed as adjusted odds ratios [AORs] with 95% confidence intervals [CIs] ) to carriage of vaccine serotype strains and nonsusceptible strains. Because (1) PCV7 became available to all children in Alaska through state programs in 2001, (2) PCV7 was introduced into the youngest age groups first, and (3) there were slight differences in the way in which the vaccine was introduced at each clinic for "catch-up" vaccination of older age groups, the variables for age, clinic, and up-to-date for age were retained in all models, regardless of statistical significance.
was considered to P ! .05 be statistically significant.
We used the variable up-to-date for age to determine the individual effect of PCV7 on carriage of PCV7-type, PCN-NS, and COT-NS pneumococci among all carriers [21] . After adjustment for whether each individual was up-to-date for age, we tested for and attributed differences in outcome variables across years to a community, or indirect, effect of PCV7.
Role of the funding source. The funding source played no role in the study design; in the collection, analysis, or interpretation of the data; in the writing of the report; or in the decision to submit the findings for publication.
RESULTS
Demographic and clinical data and vaccine uptake among enrolled children. A total of 1350 nasopharyngeal swabs were obtained from 1275 children; 75 (5.6%) of these children were enrolled in 11 year. Enrollees were similar during each study year, with respect to demographic characteristics and factors associated with pneumococcal colonization and antimicrobial resistance (table 1). The proportion of children who were up-to-date for age increased from 0% in 2000 to 55% in 2002. Of children who were up-to-date for age, 32% received 1 dose, 27% received 2 doses, 30% received 3 doses, and 11% received 4 doses. Of those who were not up-to-date for age, 88% received 0 doses, 8% received 1 dose, 3% received 2 doses, and 1% received 3 doses. Significant variation in vaccine uptake by clinic was evident. By 2002, 41%, 55%, and 69% of children at the community clinic, the private clinic, and the Alaska Native clinic, respectively, were up-to-date for age ( ). None of the children received P ! .0001 pneumococcal polysaccharide vaccine.
Trends in overall carriage of pneumococci and carriage of PCV7-type pneumococci. Overall carriage of S. pneumoniae was stable over time (table 1) . In 2000, 36%, 41%, and 37% of children at the community clinic, the private clinic, and the Alaska Native clinic, respectively, carried pneumococci (P p ). We limited the remainder of our analysis to changes ob-.58 served among carriers only.
In 2000, 54% of colonized children carried PCV7 serotypes. Carriage of vaccine serotypes decreased by 43% from 2000 to 2002 (
). Carriage of 2 of the 3 most common vaccine P ! .0001 serotypes-6B and 23F-decreased significantly, whereas carriage of serotype 19F was notably unaffected. Carriage of vaccine-related serotypes (6A and 19A) was also unaffected (figure 1). Of carriers who were up-to-date for age, 13 
]).
Trends in antimicrobial nonsusceptibility among PCV7-type and non-PCV7-type pneumococci. The prevalence of COT-NS pneumococci decreased by 38% ( ) by 2002 (table P p .02 1). Although we observed the greatest decrease in the prevalence of nonsusceptibility to COT at the Alaska Native clinic (48%; ), smaller, nonsignificant decreases occurred at the other P p .01 2 clinics. At baseline, 55 (60%) of 92 PCV7-type pneumococci were COT-NS, whereas 21 (27%) of 79 non-PCV7-type pneumococci were COT-NS (OR for association between carriage of COT-NS and PCV-type pneumococci, 4.1 [95% CI, 2.1-7.9]). Compared with that in 2000, the proportion of isolates that were COT-NS PCV7-type pneumococci decreased by 41% ( ) in 2002; the proportion of isolates that were COT-P p .005 susceptible PCV7-type pneumococci also decreased by 41% (P p .05) (figure 2). The proportion of carriers colonized with PCN-NS pneumococci remained stable over the course of the 3 years. However, substantial clinic-to-clinic variation occurred; the prevalence of nonsusceptibility to penicillin among all carriers at the Alaska Native and community clinics decreased from 41% 
up-to-date for age) and study year were not associated with overall carriage of pneumococci.
In the univariate analysis, carriage of PCV7-type pneumococci among vaccinated children tended to be lower than that among unvaccinated children (table 2) . After adjustment for clinic, study year, and age, in the multivariate analysis, children who were up-to-date for age were 40% less likely to carry PCV7 serotypes (AOR, 0.60 [95% CI, 0.36-1.0]). Furthermore, enrollment in the study after the introduction of PCV7 was associated with a reduced risk of carriage of PCV7 serotypes, independent of vaccination status: children enrolled in 2002 were 49% less likely to carry PCV7 serotypes, compared with chil- After children who had received у1 dose but were not upto-date for age were excluded, a decrease in colonization with PCV7-type pneumococci among unvaccinated children was still evident (54%, 48%, and 40% in 2000, 2001, and 2002, respectively;
). Finally, in terms of risk of carriage of P p .057 PCV7-type pneumococci, there was no difference between partially vaccinated children and unvaccinated children (AOR, 1.0 [95% CI, 0.5-2.1]).
After adjustment for clinic, study year, and age, multivariate analysis revealed that recent use of antibiotics persisted as a risk factor for carriage of COT-NS pneumococci. Neither children who were up-to-date for age nor children who were partially vaccinated were any less likely to carry COT-NS pneumococci, compared with unvaccinated children. However, risk of colonization with COT-NS pneumococci tended to be lower in Stratification of data on the basis of recent exposure to antibiotics revealed 2 patterns in the multivariate analysis. First, among those who had not received antibiotics, a smaller proportion of children who were up-to-date for age tended to have carriage of COT-NS pneumococci (13/67; 19%), compared with children who were not up-to-date for age (92/268; 34%) (P p ). Second, this relationship was not observed among carriers .07 who had received antibiotics recently. Twenty (45%) of 44 antibiotic recipients who were up-to-date for age carried COT-NS pneumococci, compared with 49 (51%) of 96 antibiotic recipients who were not up-to-date for age (
). There was no P p .26 difference in the proportion of carriage of PCV7-type pneumococci between antibiotic recipients and nonrecipients.
After adjustment for univariate risk factors for carriage of PCN-NS pneumococci, exposure to antibiotics was the only independent predictor of carriage of PCN-NS pneumococci. Of importance, children who were up-to-date for age were 50% more likely to have received antibiotics during the previous 90 days, compared with children who were not up-to-date for age (OR, 1.5 [95% CI, 1.1-2.0]). This effect was mainly due to children at the private clinic, where 45% of children who were upto-date for age had received antibiotics recently, compared with 30% of children who were not up-to-date for age ( ). P p .01 Effect of time since vaccination on overall carriage of pneumococci, carriage of vaccine serotypes, and carriage of nonsusceptible pneumococci. We also analyzed the association between recent (within 60 days) PCV7 vaccination and outcomes of carriage among children who had received at least 1 dose. After adjustment for clinic, study year, age, and use of antibiotics, recent vaccination had no impact on overall carriage of pneumococci ( ) or carriage of PCV7-type P p .90 (P p .11), COT-NS ( ), or PCN-NS ( ) pneu-P p .14 P p .83 mococci among carriers.
DISCUSSION
The present study has documented the effects of introduction of PCV7 on acquisition of antimicrobial-resistant pneumococci in a population with a high prevalence of antimicrobial-resistant pneumococci. The importance of the present study is further highlighted by the fact that introduction of PCV7 in Anchorage occurred in the midst of a PCV7 shortage [22] and by the fact that, after 2 years of vaccine use, 35% of our population still remained unvaccinated. We observed substantial reductions in carriage of PCV7-type pneumococci among chil- NOTE. CI, confidence interval; OR, odds ratio. a . P р .05 b Indicates that the subject did not attend a day-care center but had a household contact aged !5 years who did attend a day-care center. c Indicates that the subject received some PCV7 but was not up-to-date for age.
dren who were up-to-date for age (direct effect) and among children who were not up-to-date for age (indirect effect). Carriage of 2 of the 3 most common vaccine serotypes also decreased, but carriage of serotype 19F remained unchanged over the course of the 3 years of observation. Carriage of PCN-NS pneumococci was unaffected, yet the prevalence of COT-NS pneumococci decreased significantly.
The decrease in carriage of COT-NS pneumococci is noteworthy for 3 reasons. First, COT-NS pneumococci were more likely to be PCV7-type than COT-susceptible strains. Therefore, the decrease in carriage of COT-NS pneumococci is consistent with a direct and causal effect of PCV7 vaccination on reduced acquisition of COT-NS pneumococci. Second, this decrease occurred in the setting of low selective pressure from use of cotrimoxazole antibiotics; only 4%-6% of all enrolled children received cotrimoxazole each year. Finally, our finding that, independent of individual vaccination history, children enrolled in 2001 and 2002 were less likely to carry COT-NS pneumococci is a key observation. It implies that acquisition of COT-NS pneumococci was reduced among children who were not upto-date for age.
Reducing transmission of COT-NS pneumococci is an important public health challenge in developing countries, where cotrimoxazole is a first-line agent for respiratory infections. However, vaccine coverage is often lower in developing countries. Our findings show that introduction of conjugate pneumococcal vaccine in a region with high prevalence of antimicrobial resistance among pneumococci might lead to reduced transmission of antimicrobial-resistant pneumococci. What is unknown is whether reductions in transmission will translate to lower rates of noninvasive, antimicrobial-resistant pneumococcal pneumonia among unvaccinated as well as vaccinated individuals. The persistence of herd effects after Haemophilus influenzae serotype b vaccination over time is encouraging [23] . It is not known whether nonvaccine serotypes that replace those vaccine serotypes currently causing colonization, otitis media, or pneumonia will themselves develop antimicrobial resistance.
In contrast to decreases in colonization with COT-NS pneu- Are these results attributable to the introduction of the vaccine? We observed no demographic changes in the population sampled, nor were there any changes in the prevalence of use of antibiotics. Our multivariate analysis suggests a direct effect of the vaccine on carriage of PCV7-type pneumococci. Furthermore, we observed a trend toward a decreased risk of carriage of COT-NS pneumococci among vaccine recipients who did not receive antibiotics. A significant proportion of children who were vaccinated also received antibiotics, suggesting that both vaccination and antibiotic prescriptions were consequences of recent visits. This is important because it highlights the need for efforts to simultaneously increase vaccine coverage while encouraging appropriate use of antibiotics. In the present study, recent use of antibiotics was the only independent risk factor for carriage of PCN-NS pneumococci among all pneumococcal carriers, further emphasizing the potential impact that reductions in inappropriate use of antibiotics might have.
Certain aspects of the present study may be particularly applicable to introduction of pneumococcal conjugate vaccine into other countries. Unlike vaccine trials, in which subjects are fully immunized, the present study was conducted in a community where vaccine was provided routinely through clinics.
A shortage of vaccine occurred in 2001, leading to some partially immunized children, and, appropriately, limited attempts were made to catch up older children. Thus, even in 2002, only 65% of children had received у1 dose of vaccine, and many of these children had received only 1 or 2 doses. These circumstances may be similar to those that may be achieved in developing countries; finding an indirect effect of vaccine on both carriage of vaccine serotypes and carriage of COT-NS pneumococci is therefore encouraging and suggests that these effects may be realized in diverse settings.
Our findings raise an important question with respect to introduction of PCV7 and the expected impact on antimicrobial resistance. In some developing countries with very high prevalences of resistance, one might ask whether incomplete coverage-either through incomplete vaccination of many individuals or complete vaccination of fewer individuals-could be expected to reduce transmission of resistant pneumococci. Although we have presented data on vaccination in terms of partial vaccination and up-to-date for age, analysis of other parameters of vaccination, including the number of doses received and the time since the last dose, gave similar results.
Our study has certain limitations. We have reported findings after just 2 years from the introduction of vaccine. It is not yet known whether these changes will continue, become more pronounced, or reverse. Also, the trends observed in unvaccinated children could have been caused by some unmeasured factor that reduced the prevalence of PCV7 types in all children. Finally, our population likely differs from other populations [25] in terms of the baseline prevalence of nonsusceptibility and the association between nonsusceptible strains and vaccine serotypes.
In summary, our investigation has found that colonization with and transmission of COT-NS pneumococci can be reduced through introduction of PCV7 in a community. The degree to which transmission is impeded, however, is dependent on the baseline prevalence of the vaccine serotypes, the association between those serotypes and nonsusceptibility, and the proportion of children who are up-to-date for age. Finally, the ability of PCV7 to reduce transmission of nonsusceptible pneumococci may not be sustained unless its introduction is coupled with aggressive programs aimed at reducing inappropriate use of antibiotics.
